

Shalby/SE/2026-27/36

August 12, 2026

The Listing Department
National Stock Exchange of India Ltd
Mumbai 400 051.

Scrip Code : SHALBY

Through : <https://neaps.nseindia.com/NEWLISTINGCORP/>

Corporate Service Department
BSE Limited
Mumbai 400 001.

Scrip Code: 540797

Through : <http://listing.bseindia.com>

Sub: Outcome of the Board Meeting of the Company

Dear Sir / Madam,

In continuation of our intimation letter no. Shalby/SE/2026-27/28 dated July 15, 2026, letter no. Shalby/SE/2026-27/32 dated July 27, 2026 and pursuant to Regulation 30, 33 and other applicable provisions of LODR Regulations, as amended from time to time, we would like to inform you that the Board of Directors of Shalby Limited (the "Company") at its meeting held today, i.e. Wednesday, August 12, 2026 which commenced at 5:13 p.m. and concluded at 6.15 p.m. has inter alia transacted the following businesses:

1. Unaudited Financial Results

Considered and approved Unaudited Standalone and Consolidated Financial results for the quarter ended June 30, 2026, together with the Limited Review Report issued by the Statutory Auditors of the Company thereon. The said financial results along with Limited Review Report are attached herewith as Annexure – A and are available on the website of the Company at www.shalby.org

2. Cost Audit Report

Considered and approved Cost Audit Report on the cost records of the Company for the financial year ended March 31, 2026 issued by M/s. Borad Sanjay B & Associates, Cost Accountants.

3. Appointment of Whole-Time Director

Considered and approved appointment of Mr. Shanay Vikram Shah (DIN: 02726541) as an Additional Director designated as Whole-Time Director for a term of five consecutive years with effect from August 12, 2026, pursuant to the recommendation of the Nomination and Remuneration Committee, prior approval of Audit Committee and, subject to the approval of shareholders at the ensuing Annual General Meeting. He shall also be designated as a Key Managerial Personnel of the Company as per Section 203 of the Companies Act, 2013.

SHALBY LIMITED

Regd. Office: Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India.

Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org

CIN: L85110GJ2004PLC044667

Mr. Shanay Vikram Shah is not disqualified or debarred from holding the office of Director pursuant to any order issued by Securities and Exchange Board of India or any other such authority, and declaration to this effect has been obtained pursuant to BSE Circular No. LIST/COMP /14/2018-19 dated June 20, 2018, and NSE Circular No. NSE/ CML/2018/24 dated June 20, 2018.

Mr. Shanay Vikram Shah, shall hold office as an Additional Director designated as Whole-Time Director until the conclusion of the ensuing Annual General Meeting. The matter of his appointment as Whole-Time Director for a term of five consecutive years with effect from August 12, 2026 is being placed before the shareholders for approval at the ensuing 22nd Annual General Meeting scheduled to be held on Thursday, September 10, 2026.

The details relating to appointment of Director as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure – B.

4. Appointment of Internal Auditors

Considered and approved appointment of M/s. PricewaterhouseCoopers Services LLP, Chartered Accountants, as Internal Auditors of the Company for the financial year 2026-27, as recommended by Audit Committee of the Company.

5. Approval of Notice of 22nd Annual General Meeting

Approved Notice for convening the 22nd Annual General Meeting of the Members of the Company, scheduled to be held on Thursday, September 10, 2026 at 4:00 p.m. IST.

6. Acquisition of remaining 0.67% shares by Shalby Medtech Limited (Earlier known as Mars Medical Devices Limited) in Shalby Global Technologies Pte. Ltd.

The Board of Directors took note of the acquisition of 10,000 equity shares representing 0.67% equity share capital of Shalby Global Technologies Pte. Ltd., Singapore (Step-down subsidiary of the Company) by Shalby Medtech Limited (Earlier known as Mars Medical Devices Limited) (Wholly-owned subsidiary of the Company) from Dr. Vikram Shah and Mr. Shanay Shah.

Post-acquisition, Shalby Global Technologies Pte. Ltd. is now a wholly-owned subsidiary of Shalby Medtech Limited, effective from August 12, 2026.

SHALBY LIMITED

Regd. Office: Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India.

Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org

CIN: L85110GJ2004PLC044667

The details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with read with SEBI Circular CIR/CFD/CMD/4/2015 dated 09 September, 2015 are enclosed herewith as Annexure – C.

We request to take the same on your records.

Thanking you,

For **Shalby Limited**

Tushar Shah
Vice President & Company Secretary
Mem. No. F7216

Encl.: As above

Annexure – B

Details under Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 09 September, 2015

Sr.	Particulars	Disclosures
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Shanay Vikram Shah (DIN: 02726541) as an Additional Director designated as Whole-Time Director for a term of five consecutive years, with effect from August 12, 2026, subject to the approval of Shareholders at the ensuing Annual General Meeting
2	Date of appointment / cessation (as applicable) & term of appointment	Appointment for a term of five consecutive years, with effect from August 12, 2026.
3	Brief profile (in case of appointment)	Mr. Shanay Vikram Shah, aged 35 years, holds a Bachelor's degree in Science with Honors in Accounting and Finance from the University of Warwick, United Kingdom, and a Master's degree in International Health Management from Imperial College London, United Kingdom. He is also a Chartered Financial Analyst (CFA). Mr. Shanay Vikram Shah is one of the Promoters of the Company and is a relative of Dr. Vikram I. Shah (DIN: 00011653), Promoter, Chairman and Managing Director of the Company and has been associated with the Company since October 5, 2013, with over a decade of experience in the healthcare industry, including but not limited to oversight of the Company's business including international business, strategy, financial operations, Human Resource, and investor relations. He was earlier appointed as President of the Company to hold an office or place of profit for a term of five years with effect from October 5, 2024. He is a key member of the Youth Presidents' Organization (YPO) and is associated with industry chambers including CII, ICC, FICCI and ASSOCHAM.
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Shanay Vikram Shah is related to Dr. Vikram Shah (DIN: 00011653), Promoter, Chairman and Managing Director of the Company, being his son.

Mr. Shanay Vikram Shah (DIN: 02726541) is not debarred from holding of office of Director pursuant to any order issued by Securities and Exchange Board of India or any other such authority.

SHALBY LIMITED

Regd. Office: Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India.

Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org

CIN: L85110GJ2004PLC044667

Annexure – C

Details under Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 09 September, 2015

Sr. No.	Particulars	Details
1	Name of Target Entity	Shalby Global Technologies Pte. Ltd., Step-down subsidiary of the Company (“SGTPL”) Shalby Medtech Limited (Earlier known as Mars Medical Devices Limited) (Wholly-owned subsidiary) has acquired 10,000 equity shares representing 0.67% equity share capital of SGTPL from Dr. Vikram Shah and Mr. Shanay Shah.
	Details in brief such as size, Turnover etc.;	Paid up Share Capital: Paid-up Equity Share Capital : 14,89,000 Equity Shares of SGD 1 each Paid-up Preference Share Capital 4,00,000 Preference Shares of SGD 1 each. Turnover for FY 2025-26: SGD 9,11,671
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired?	The transaction falls within related party transaction. The shares have been acquired from Dr. Vikram Shah and Mr. Shanay Shah, who were the existing shareholders of SGTPL.
	If yes, nature of interest and details thereof and whether the same is done at “arms length”	The Promoters of the Company have interest in the above entity to the extent of their Directorship and Membership in Shalby Medtech Limited and SGTPL. The transaction has been undertaken at arms’ length basis at a consideration of SGD 2 per share aggregating to SGD 20,000, based on the valuation of the shares as determined pursuant to a valuation report obtained from a SEBI-registered Category I Merchant Banker.
3	Industry to which the entity being acquired belongs	Wholesale of medical, professional, scientific and precision equipment

SHALBY LIMITED

Regd. Office: Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India.

Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org

CIN: L85110GJ2004PLC044667

4	Objects and impact of acquisition (including but not limited to, disclosure of reason for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Shalby Medtech Limited has acquired 10,000 equity shares, representing 0.67% of the equity share capital of SGTPL. Accordingly, SGTPL is now the wholly-owned subsidiary of Shalby Medtech Limited, effective from August 12, 2026.
5	Brief details of any governmental or regulatory approval required for acquisition	Not applicable.
6	Indicative time period for completion of the acquisition	The acquisition by Shalby Medtech Limited has completed on August 12, 2026 upon approval of Board of Directors of respective companies.
7	Nature of Consideration- Whether cash Consideration? Or Share Swap and details of the same	Cash consideration.
8	Cost of acquisition and/or the price at which the shares are acquired;	Shalby Medtech Limited has acquired 10,000 equity shares of SGTPL at a consideration of SGD 2 per equity share, aggregating to SGD 20,000.
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Shalby Medtech Limited has acquired 10,000 equity shares, representing 0.67% of the equity share capital of SGT. Accordingly, SGTPL is now the wholly-owned subsidiary of Shalby Medtech Limited, effective from August 12, 2026.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Shalby Global Technologies Pte. Ltd. is a company incorporated in Singapore and is engaged in the business of Wholesale of medical, professional, scientific and precision equipment. It was already a 99.33% subsidiary of Shalby Medtech Limited and a step-down subsidiary of Shalby Limited prior to the acquisition. Upon acquisition of 0.67% shareholding, SGTPL has now become a wholly-owned subsidiary of Shalby Medtech Limited and consequently a wholly-owned step-down subsidiary of Shalby Limited effective from August 12, 2026. The turnover of SGTPL for the last three financial years is as follows: FY 2025-26: SGD 9,11,671 FY 2024-25: SGD 10,08,752 FY 2023-24: SGD 2,32,342

SHALBY LIMITED

Regd. Office: Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India.

Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org

CIN: L85110GJ2004PLC044667

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**TO THE BOARD OF DIRECTORS OF
SHALBY LIMITED**

1. We have reviewed the accompanying "Statement of Unaudited Standalone Financial Result of **Shalby Limited** ("the Company") for the quarter ended June 30,2026" ("the statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of The SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015, as amended ('the Listing Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29,2019 ('the Circular').
2. The preparation of the Statement is in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with standards on Auditing and Consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedure performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in

accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed, or that it contain any material misstatement.

For, T R Chadha & Co LLP

Chartered Accountants

Firm Regn. No: 006711N / N500028

Arvind Modi



Arvind Modi

(Partner)

M. No.: 112929

UDIN: - 26112929EPFNPPH172

Place: Ahmedabad

Date: August 12, 2026

Shalby Limited

Regd. Office : Opp. Karnavati Club, Sarkhej Gandhinagar Highway,
Near Prahlad Nagar Garden, Ahmedabad – 380 015, Gujarat, India
Phone: +91 79 40203000, Fax :+91 79 40203120
E-mail : companysecretary@shalby.in Website : www.shalby.org
CIN : L85110GJ2004PLC044667

SHALBY LIMITED

•Passion•Compassion•Innovation•

Statement of Unaudited Standalone Financial results for the Quarter ended June 30, 2026

Part I


[₹ in Million except per share data]

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited Refer Note - 3	Unaudited	Audited
	Income				
I	Revenue from Operations	2,537.91	2,248.54	2,365.64	8,985.58
II	Other Income	52.75	55.92	56.13	248.57
III	Total Income (I+II)	2,590.66	2,304.46	2,421.77	9,234.15
	Expenses				
IV	Operative Expenses	1,590.72	1,397.01	1,444.81	5,548.66
	Purchase of stock in trade	43.37	34.63	31.56	135.79
	Changes in Inventories	(3.21)	(0.13)	(0.20)	(4.96)
	Employee benefits expense	298.36	293.89	268.23	1,124.14
	Finance Costs	30.77	23.58	25.84	127.76
	Depreciation and amortisation expenses	108.01	105.34	96.81	401.49
	Other Expenses	183.79	208.56	153.71	734.36
	Total Expenses (IV)	2,251.81	2,062.88	2,020.76	8,067.24
V	Profit / (loss) before exceptional items and tax (III-IV)	338.85	241.58	401.01	1,166.91
VI	Exceptional Items	-	(6.96)	-	(6.96)
VII	Profit / (Loss) before tax (V+VI)	338.85	234.62	401.01	1,159.95
VIII	Tax Expense:				
	(1) Current Tax	114.86	(19.37)	179.90	364.68
	(2) Adjustment of earlier years	-	15.11	-	16.15
	(3) MAT Credit written off	-	42.36	-	42.36
	(4) Deferred Tax	(26.67)	(340.16)	(35.84)	(392.34)
IX	Profit/(Loss) for the period from continuing operations (VII-VIII)	250.66	536.68	256.95	1,129.10
X	Profit/(Loss) from discontinued operations	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	250.66	536.68	256.95	1,129.10
XIV	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or (loss)	(0.58)	0.04	0.78	(2.31)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.15	(0.24)	(0.27)	0.58
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be re classified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	250.23	536.48	257.46	1,127.37
XVI	Comprising Profit / (Loss) and Other Comprehensive Income for the period)	250.23	536.48	257.46	1,127.37
XVI	Paid-up Equity Share Capital (Face value of ₹ 10/- each) (net of Treasury Shares)	1,075.26	1,075.19	1,074.87	1,075.19
XVII	Reserve excluding revaluation reserves as per balance sheet of previous accounting year				11,394.20
XVIII	Earnings per equity share ₹ 10/- each (for Continuing operation):				
	(1) Basic	2.33	4.99	2.39	10.50
	(2) Diluted	2.33	4.99	2.39	10.50
XIX	Earnings per equity (for discontinued operation)				
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-

Notes to the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026

- The above unaudited financial results for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and subsequently approved
- 1) by the Board of Directors of the company at their respective meetings held on August 12, 2026. The Statutory Auditors of the Company have carried out a Limited Review for said unaudited financial results.
 - 2) These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.
 - 3) The figures for quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year-to-date figures up to the third quarter of the financial year.
 - 4) Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. Till June 30, 2026, Company has granted all 7,00,000 Stock Options to eligible employees, out of which total 4,42,765 Stock Options were lapsed and 2,16,235 options were vested and exercised by eligible employees.
 - 5) In accordance with the resolution passed by Nomination and Remuneration Committee, the company has granted 1,33,000 stock options from the pool of 4,42,765 lapsed options. As of June 30, 2026, a total of 1,10,000 stock options remain active.
 - 6) The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated November 26, 2018.
 - 7) The company's operating segment is "Medical and Healthcare Related Services". Since the company has a single operating segment, disclosure pertaining to segment as per the regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.
 - 7) Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable.

Place : Ahmedabad
Date : August 12, 2026



For Shalby Limited

Dr. Vikram Shah
Chairman and Managing Director
DIN: 00011653



Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**TO THE BOARD OF DIRECTORS OF
SHALBY LIMITED**

1. We have reviewed the accompanying statement of unaudited Consolidated Financial Results of **Shalby Limited** ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred to as "the group"), for the quarter ended June 30, 2026 ("the statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended ('the Listing Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the companies Act, 2013 as amended, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the standard on review Engagements (SRE) 2410 "Review of interim Financial Information performed by the Independent Auditor of the Entity.", issued by the Institute of Chartered accountants of India. A review of interim financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with standards on Auditing and Consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 as amended to the extent applicable.



4. The statement includes the results of the following entities;

	Holding Company
1	Shalby Limited
	Subsidiary Companies
2	Shalby (Kenya) Limited
3	Vrundavan Shalby Hospitals Limited
4	Yogeshwar Healthcare Limited
5	Shalby International Limited
6	Griffin Mediquip LLP
7	Shalby MedTech Limited (Earlier known as Mars Medical Devices Limited)
8	Slaney Healthcare Private Limited
9	Shalby Hospitals Mumbai Private Limited
10	PK Healthcare Private Limited
11	Healers Hospital Private Limited
12	Shalby Advanced Technologies INC. (Step Down Subsidiary)
13	Shalby Global Technologies Pte Ltd. (Step Down Subsidiary)
14	Shalby Advanced Technologies India Private Limited (Step Down Subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information given by management referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed , or that it contain any material misstatement.
6. The accompanying statement includes audited interim financial results / financial information in respect of 12 subsidiaries whose interim financial results / financial information reflects, total revenues of ₹ 1,362.44 Million, total net loss after tax of ₹ 139.68 Million, and total comprehensive loss of ₹ 134.71 Million for the quarter ended June 30,



2026 as considered in the statement whose financial results / financial information have been audited by us.

We did not audit the financial results \ statements and other financial information, in respect of 1 subsidiary total revenue of ₹ **0.08 Million** total net Loss after tax of ₹ **0.74 Million** total comprehensive Loss ₹ **0.73 Million** for the quarter ended June 30, 2026 as considered in the financial statement.

Our conclusion on the Statement is not modified in respect of the above matters.

For, T R Chadha & Co LLP
Chartered Accountants
Firm Regn. No: 006711N / N500028

Arvind Modi

Arvind Modi
(Partner)

M. No.: 112929

UDIN: - 26112929AKVKCI4106



Place: Ahmedabad
Date: August 12, 2026

Shalby Limited

Regd. Office : Opp. Karnavati Club, Sarkhej Gandhinagar Highway,
Near Prahlad Nagar Garden, Ahmedabad – 380 015, Gujarat, India
Phone: +91 79 40203000, Fax :+91 79 40203120
E-mail : Groupsecretary@shalby.in Website : www.shalby.org
CIN : L85110GJ2004PLC044667

SHALBY
LIMITED


•Passion•Compassion•Innovation•

Statement of Unaudited Consolidated Financial results for the Quarter ended June 30, 2026

Part I

[₹ in Million except per share data]

Sr. No.	Particulars	Quarter ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited Refer Note - 3	Unaudited	Audited
	Income				
I	Revenue from Operations	3,312.24	2,874.45	2,964.26	11,414.29
II	Other Income	74.14	80.79	70.08	267.91
III	Total Income (I+II)	3,386.38	2,955.24	3,034.34	11,682.20
	Expenses				
IV	Cost of Material Consumed	82.41	149.47	154.57	647.98
	Operative Expenses	1,460.37	1,285.41	1,406.64	5,235.91
	Purchase of Stock In Trade	420.10	412.48	293.41	1,339.37
	Changes In Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	134.43	(127.14)	(66.00)	(474.35)
	Employee Benefits Expense	478.58	495.60	465.10	1,882.93
	Finance Costs	105.65	93.38	93.71	389.95
	Depreciation and Amortisation Expenses	187.44	184.85	165.23	699.87
	Other Expenses	320.45	365.15	295.16	1,354.93
	Total Expenses (IV)	3,189.43	2,859.18	2,807.81	11,076.59
V	Profit / (loss) before exceptional items and tax (III-IV)	196.95	96.06	226.53	605.61
VI	Exceptional Items	-	-	-	-
VII	Profit / (Loss) before tax (V+VI)	196.95	96.06	226.53	605.61
VIII	Tax Expense:				
	(1) Current Tax	119.47	(14.78)	183.44	381.68
	(2) Adjustment of earlier years	-	14.71	-	16.18
	(3) MAT Credit written off	-	42.36	-	42.36
	(4) Deferred Tax	(27.48)	(130.77)	(33.69)	(181.47)
IX	Profit/(Loss) for the period from continuing operations (VII-VIII)	104.96	184.54	76.78	346.87
X	Profit/(Loss) from discontinued operations	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	104.96	184.54	76.78	346.87
XIV	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	(0.58)	3.89	0.78	1.54
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.15	(0.49)	(0.27)	0.33
	B. (i) Items that will be reclassified to profit or loss	4.98	(147.55)	(5.09)	(249.19)
	(ii) Income tax relating to items that will be re classified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other Comprehensive Income for the period	109.51	40.39	72.19	99.53
XVI	Profit for the year attributable to				
	Shareholders of the Group	108.45	183.19	89.22	373.89
	Non-Controlling Interest	(3.49)	1.36	(12.44)	(27.02)
XVII	Other comprehensive income attributable to				
	Shareholders of the Group	4.55	(144.36)	(4.58)	(247.54)
	Non-Controlling Interest	-	0.20	0.01	0.21
XVIII	Total comprehensive income for the year attributable to				
	Shareholders of the Group	113.00	38.83	84.63	126.34
	Non-Controlling Interest	(3.49)	1.56	(12.44)	(26.81)
XVI	Paid-up Equity Share Capital (Face value of ₹ 10/- each) (net of Treasury Shares)	1,075.26	1,075.19	1,074.87	1,075.19
XVII	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	-	-	-	8,977.15
XVIII	Earnings per equity share ₹ 10/- each (for Continuing operation):				
	(1) Basic	0.98	1.72	0.71	3.23
	(2) Diluted	0.98	1.72	0.71	3.23
XIX	Earnings per equity (for discontinued operation)				
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-




[Handwritten signature]

Notes to the Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026

- The above unaudited financial results for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on August 12, 2026. The Statutory Auditors of the Company have carried out a Limited Review for said unaudited financial results.
- 1) These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.
- 2) The figures for quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year-to-date figures up to the third quarter of the financial year.
- 3) Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. Till June 30, 2026, Company has granted all 7,00,000 Stock Options to eligible employees, out of which total 4,42,765 Stock Options were lapsed and 2,16,235 options were vested and exercised by eligible employees.
- 4) In accordance with the resolution passed by Nomination and Remuneration Committee, the company has granted 1,33,000 stock options from the pool of 4,42,765 lapsed options. and as As of June 30, 2026, a total of 1,10,000 stock options remain active.
- 5) Shalby Medtech Limited ("SMTL") (Wholly Owned Subsidiary Company of Holding Company), have implemented Employee Stock Option Scheme, namely Shalby Medtech Limited - Employees Stock Options Scheme – 2025, as approved by its shareholders. During quarter ended June 30, 2026, SMTL has granted 50,000 Stock Options convertible into equivalent number of equity shares of SMTL upon vesting, pursuant to said ESOP scheme. As on June 30, 2026, SMTL has granted total 11,41,000 Stock Options
- 6) Shalby Medtech Limited ("SMTL"), a Wholly-Owned Subsidiary of the Holding Company, at its meeting held today have approved acquisition of balance 10,000 equity shares of Shalby Global Technologies Pte. Ltd. ("SGTPL"), Singapore, from two individual promoter shareholders. Consequently, SGTPL has become a wholly-owned subsidiary of SMTL with effect from August 12, 2026.
- 7) The consolidated financial result includes the results of the Company and 13 Subsidiary companies (Covering 3 stepdown subsidiaries). The company together with its subsidiaries is herein referred to as the "Group".
- 8) The Group is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated November 26, 2018.
- 9) As per Indian Accounting Standard ("Ind AS") 108 - "Segment Reporting", segment information has been provided in Consolidated Financial Results. The business segments of the company comprise of Healthcare Activities & Manufacturing of Implant. Disclosure for the same is given in the separate note attached herewith in Annexure I.
- 10) Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable.

Place : Ahmedabad

Date : August 12, 2026



For Shalby Limited

Dr. Vikram Shah

Chairman and Managing Director

DIN: 00011653



Shalby Limited**Segment wise Revenue, Results, Segment Assets and Segment Liabilities**

As per Indian Accounting Standard 108 'Operating Segments', the Group has reported 'Segment Information', as described below:

a) The Healthcare Services segment includes business of setting up and managing hospitals and medical diagnostics services.

b) The Manufacturing segment represents manufacturing & trading of Implants.

[₹ in Million]

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Unaudited	Audited Refer Note - 3	Unaudited	Audited
I	Segment Revenue				
	a) Healthcare Services	2,888.14	2,472.32	2,683.63	10,101.36
	b) Manufacturing & Trading of Implants	424.10	402.13	280.62	1,312.92
	Income from Operations	3,312.24	2,874.45	2,964.26	11,414.29
II	Segment Results				
	a) Healthcare Services	311.76	170.76	325.67	952.82
	b) Manufacturing & Trading of Implants	(114.81)	(74.71)	(99.15)	(347.21)
	Profit / (Loss) Before Tax	196.95	96.06	226.52	605.61
III	Capital employed				
	a) Healthcare Services				
	Segment Assets	12,704.34	12,649.66	12,872.15	12,649.66
	Segment Liabilities	(4,125.32)	(4,127.94)	(4,493.53)	(4,127.94)
	b) Manufacturing & Trading of Implants				
	Segment Assets	5,836.05	5,741.63	4,868.80	5,741.63
	Segment Liabilities	(4,243.93)	(4,206.42)	(3,238.45)	(4,206.42)
	Total Capital Employed	10,171.14	10,056.92	10,008.97	10,056.92

